French pharmaceutical company Sanofi has announced plans to invest €1.3 billion in the construction of a new insulin production facility in Germany. The new facility will replace the current production sites in Höchst, near Frankfurt, and is expected to be completed by 2029. The project aims to ensure the long-term supply of essential insulin for people living with diabetes and strengthen the resilience of European healthcare.
The investment has received support from both the German federal government and the state government of Hesse. Sanofi Germany CEO Heidrun Irschik-Hadjieff described it as an important signal for the biopharmaceutical industry.
This investment follows similar announcements by US pharmaceutical company Eli Lilly, which plans to invest €2.3 billion to expand its diabetes medication production in Germany, and Danish company Novo Nordisk, the leading global insulin manufacturer, which is investing €2.1 billion to expand its production facility in France.
Sanofi's current Höchst site covers the entire insulin production chain, from the manufacturing of the active ingredient to the distribution of injections worldwide.
infobud.news is an AI-driven news aggregator that simplifies global news, offering customizable feeds in all languages for tailored insights into tech, finance, politics, and more. It provides precise, relevant news updates, overcoming conventional search tool limitations. Due to the diversity of news sources, it provides precise and relevant news updates, focusing entirely on the facts without influencing opinion. Read moreExpand